Market Closed -
Nasdaq
02:00:01 04/05/2024 am IST
|
5-day change
|
1st Jan Change
|
0.8504
USD
|
+0.05%
|
|
-4.41%
|
-23.04%
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Capitalization
1 |
349.6
|
225.2
|
171.1
|
105.5
|
30.78
|
23.69
|
-
|
-
|
Enterprise Value (EV)
1 |
349.6
|
225.2
|
171.1
|
105.5
|
30.78
|
23.69
|
23.69
|
23.69
|
P/E ratio
|
-13.6
x
|
-7.53
x
|
52.9
x
|
-7.02
x
|
-1.09
x
|
-1.21
x
|
-2.07
x
|
-2.36
x
|
Yield
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
15.3
x
|
25.7
x
|
5.47
x
|
27.2
x
|
19.8
x
|
9.87
x
|
3.88
x
|
2.92
x
|
EV / Revenue
|
15.3
x
|
25.7
x
|
5.47
x
|
27.2
x
|
19.8
x
|
9.87
x
|
3.88
x
|
2.92
x
|
EV / EBITDA
|
-1,39,50,647
x
|
-80,22,004
x
|
3,77,57,913
x
|
-
|
-
|
-
|
-
|
-
|
EV / FCF
|
-15.1
x
|
-8.77
x
|
-21.8
x
|
-10.9
x
|
-
|
-1.16
x
|
-1.44
x
|
-1.72
x
|
FCF Yield
|
-6.61%
|
-11.4%
|
-4.58%
|
-9.15%
|
-
|
-86.5%
|
-69.2%
|
-58.3%
|
Price to Book
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Nbr of stocks (in thousands)
|
20,387
|
23,001
|
23,119
|
23,129
|
27,858
|
27,858
|
-
|
-
|
Reference price
2 |
17.15
|
9.790
|
7.400
|
4.560
|
1.105
|
0.8504
|
0.8504
|
0.8504
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net sales
1 |
22.9
|
8.771
|
31.27
|
3.883
|
1.554
|
2.4
|
6.1
|
8.1
|
EBITDA
|
-25.06
|
-28.07
|
4.531
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
-25.95
|
-30.23
|
2.964
|
-16.24
|
-29.3
|
-21.1
|
-15.9
|
-13.9
|
Operating Margin
|
-113.3%
|
-344.69%
|
9.48%
|
-418.34%
|
-1,885.78%
|
-879.17%
|
-260.66%
|
-171.6%
|
Earnings before Tax (EBT)
1 |
-24.58
|
-29.29
|
3.221
|
-14.92
|
-27.24
|
-19.7
|
-14.4
|
-12.9
|
Net income
1 |
-24.61
|
-29.29
|
3.221
|
-14.92
|
-27.24
|
-19.7
|
-14.4
|
-12.9
|
Net margin
|
-107.44%
|
-333.94%
|
10.3%
|
-384.32%
|
-1,752.77%
|
-820.83%
|
-236.07%
|
-159.26%
|
EPS
2 |
-1.260
|
-1.300
|
0.1400
|
-0.6500
|
-1.010
|
-0.7000
|
-0.4100
|
-0.3600
|
Free Cash Flow
1 |
-23.1
|
-25.69
|
-7.834
|
-9.655
|
-
|
-20.5
|
-16.4
|
-13.8
|
FCF margin
|
-100.84%
|
-292.9%
|
-25.05%
|
-248.65%
|
-
|
-854.17%
|
-268.85%
|
-170.37%
|
FCF Conversion (EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Fiscal Period: December |
2021 Q3
|
2021 Q4
|
2022 Q1
|
2022 Q2
|
2022 Q3
|
2022 Q4
|
2023 Q1
|
2023 Q2
|
2023 Q3
|
2023 Q4
|
2024 Q1
|
2024 Q2
|
2024 Q3
|
2024 Q4
|
---|
Net sales
1 |
1.336
|
20.81
|
0.003
|
3.518
|
0.261
|
0.1
|
0.758
|
0.594
|
0.213
|
0.447
|
1.3
|
0.3
|
0.4
|
0.4
|
EBITDA
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
EBIT
1 |
1.272
|
13.96
|
-5.95
|
-0.463
|
-3.625
|
-6.205
|
-10.6
|
-6.527
|
-6.307
|
-5.407
|
-4.7
|
-5.6
|
-5.4
|
-5.4
|
Operating Margin
|
95.21%
|
67.08%
|
-1,98,333.33%
|
-13.16%
|
-1,388.89%
|
-6,205%
|
-1,399.08%
|
-1,098.82%
|
-2,961.03%
|
-1,209.62%
|
-361.54%
|
-1,866.67%
|
-1,350%
|
-1,350%
|
Earnings before Tax (EBT)
1 |
1.286
|
14.03
|
-5.597
|
-0.134
|
-3.407
|
-5.785
|
-10.26
|
-5.97
|
-5.711
|
-4.836
|
-4.2
|
-5.2
|
-5.1
|
-5.2
|
Net income
1 |
1.286
|
14.03
|
-5.597
|
-0.134
|
-3.407
|
-5.785
|
-10.26
|
-5.97
|
-5.711
|
-4.836
|
-4.2
|
-5.2
|
-5.1
|
-5.2
|
Net margin
|
96.26%
|
67.43%
|
-1,86,566.67%
|
-3.81%
|
-1,305.36%
|
-5,785%
|
-1,353.96%
|
-1,005.05%
|
-2,681.22%
|
-1,081.88%
|
-323.08%
|
-1,733.33%
|
-1,275%
|
-1,300%
|
EPS
2 |
0.0500
|
0.6100
|
-0.2400
|
-0.0100
|
-0.1500
|
-0.2500
|
-0.4100
|
-0.2200
|
-0.2100
|
-0.1700
|
-0.1500
|
-0.1700
|
-0.1750
|
-0.1750
|
Dividend per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
12/11/21
|
30/03/22
|
13/05/22
|
04/08/22
|
10/11/22
|
10/03/23
|
12/05/23
|
10/08/23
|
09/11/23
|
13/03/24
|
-
|
-
|
-
|
-
|
Fiscal Period: December |
2019
|
2020
|
2021
|
2022
|
2023
|
2024
|
2025
|
2026
|
---|
Net Debt
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Net Cash position
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Free Cash Flow
1 |
-23.1
|
-25.7
|
-7.83
|
-9.66
|
-
|
-20.5
|
-16.4
|
-13.8
|
ROE (net income / shareholders' equity)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
ROA (Net income/ Total Assets)
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Assets
1 |
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Book Value Per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Cash Flow per Share
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
-
|
Capex
1 |
0.6
|
0.45
|
0.14
|
0.17
|
-
|
0.2
|
0.2
|
0.2
|
Capex / Sales
|
2.61%
|
5.12%
|
0.46%
|
4.4%
|
-
|
8.33%
|
3.28%
|
2.47%
|
Announcement Date
|
24/03/20
|
04/03/21
|
30/03/22
|
10/03/23
|
13/03/24
|
-
|
-
|
-
|
Last Close Price
0.8504
USD Average target price
8
USD Spread / Average Target +840.73% Consensus |
1st Jan change
|
Capi.
|
---|
| -23.04% | 23.69M | | +8.96% | 105B | | -1.43% | 104B | | +4.40% | 22.94B | | -12.15% | 22.34B | | -4.36% | 19.25B | | -39.98% | 17.08B | | -10.04% | 16.96B | | +38.61% | 12.63B | | +313.59% | 8.49B |
Bio Therapeutic Drugs
|